Arizona State Retirement System Raises Position in Axonics, Inc. (NASDAQ:AXNX)

Arizona State Retirement System raised its stake in Axonics, Inc. (NASDAQ:AXNXFree Report) by 2.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 14,345 shares of the company’s stock after acquiring an additional 311 shares during the period. Arizona State Retirement System’s holdings in Axonics were worth $805,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Mackenzie Financial Corp bought a new position in Axonics during the third quarter worth about $68,499,000. Jennison Associates LLC grew its position in Axonics by 12.2% during the 3rd quarter. Jennison Associates LLC now owns 225,957 shares of the company’s stock worth $12,681,000 after acquiring an additional 24,631 shares during the last quarter. Lisanti Capital Growth LLC boosted its holdings in Axonics by 359.0% in the third quarter. Lisanti Capital Growth LLC now owns 75,550 shares of the company’s stock valued at $4,240,000 after acquiring an additional 59,090 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in Axonics by 67.3% in the second quarter. Canada Pension Plan Investment Board now owns 107,400 shares of the company’s stock valued at $5,420,000 after buying an additional 43,200 shares during the period. Finally, Polar Asset Management Partners Inc. bought a new position in Axonics in the 2nd quarter valued at about $13,112,000. 99.00% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. CL King reaffirmed a “neutral” rating on shares of Axonics in a report on Friday, January 12th. Morgan Stanley decreased their target price on shares of Axonics from $76.00 to $69.00 and set an “overweight” rating for the company in a research note on Tuesday, October 31st. Wells Fargo & Company restated an “equal weight” rating and set a $71.00 target price (up from $68.00) on shares of Axonics in a research report on Wednesday, January 10th. Truist Financial reiterated a “hold” rating and set a $71.00 target price (down from $73.00) on shares of Axonics in a research report on Friday, January 12th. Finally, Wolfe Research cut Axonics from an “outperform” rating to a “peer perform” rating in a report on Tuesday, January 9th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $71.09.

Get Our Latest Research Report on Axonics

Insiders Place Their Bets

In other Axonics news, insider Karen Noblett sold 11,288 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total transaction of $764,649.12. Following the transaction, the insider now owns 34,428 shares of the company’s stock, valued at approximately $2,332,152.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Axonics news, insider Karen Noblett sold 11,288 shares of Axonics stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total transaction of $764,649.12. Following the sale, the insider now owns 34,428 shares of the company’s stock, valued at approximately $2,332,152.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kari Leigh Keese sold 3,489 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total transaction of $236,344.86. Following the completion of the sale, the chief financial officer now directly owns 43,323 shares of the company’s stock, valued at $2,934,700.02. The disclosure for this sale can be found here. Insiders sold 89,836 shares of company stock worth $6,069,704 in the last 90 days. Corporate insiders own 1.85% of the company’s stock.

Axonics Trading Down 0.4 %

Shares of Axonics stock opened at $67.80 on Thursday. The firm’s 50-day moving average price is $63.35 and its 200 day moving average price is $58.76. The firm has a market capitalization of $3.43 billion, a PE ratio of -271.20 and a beta of 0.63. Axonics, Inc. has a twelve month low of $47.59 and a twelve month high of $69.68.

Axonics Profile

(Free Report)

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction.

Recommended Stories

Want to see what other hedge funds are holding AXNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axonics, Inc. (NASDAQ:AXNXFree Report).

Institutional Ownership by Quarter for Axonics (NASDAQ:AXNX)

Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.